43 results about "Doxepin+Metabolites" patented technology

The invention is directed to a method for the treatment of a patient suffering from transient or short term insomnia. The claimed method comprises the administration of a compound selected from the group consisting of the pharmaceutically acceptable forms of doxepin, amitriptyline, trimipramine, trazodone and mixtures thereof in dosages ranging from about 0.5 to about 20.0 milligrams.

Methods of improving the pharmacokinetics of doxepin in a patient.

The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.

Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals.

Methods of treating sleep disorders by administration of low doses of doxepin in individuals seeking sustained efficacy or in need of avoiding weight gain, rebound insomnia, or sedative tolerance resulting from doxepin treatment.

The invention provides a method for synthesizing doxepin hydrochloride. The method comprises the following steps of: 1, carrying out an addition reaction on 6,11-dihydrobenz [b,e] oxepin-11-one and 3-chloropropyl-methyl tert-butyl ether to obtain alcohol compounds; 2, removing hydroxyl from the alcohol compounds under the condition of concentrated hydrochloric acid to obtain olefin compounds; 3, reacting the olefin compounds with thionyl chloride in a reaction solvent to obtain chloride; 4, coupling the chloride with N,N-dimethyl methylamine to obtain doxepin; and 5, preparing the doxepin into hydrochloride of the doxepin to obtain the doxepin hydrochloride. An Ni(OAc)2 / PPh3 system is creatively used in C-N coupling reaction in the step 4, thus the doxepin hydrochloride has the characteristics of good reaction selectivity, high yield and environmental friendliness; and the catalyst is can be recycled after being simply filtered, thus the production cost is greatly lowered. The whole method has the advantages of simpleness in operation, and easy obtaining and low cost of raw materials, accords with the requirement of industrial production, and is expected to be industrially applied.

The invention relates to the new application of asiatic acid and its derivatives in the preparation of antidepressants. Experiments have proved that asiatic acid and its derivatives, as well as the pharmaceutical composition, are safe, efficient, stable, and cheap drugs for preventing and treating depression, all of which have relatively high activity, especially asiatic acid, centella asiatica Compounds such as sodium oxalate are more active than doxepin.

The invention provides gargle for preventing and treating mouth mucositis caused by chemoradiotherapy. The gargle is prepared from hydrochloric acid doxepin, glycerol, dimethyl sulfoxide and purified water. Every 100 ml of the gargle is prepared from 0.1-10 g of hydrochloric acid doxepin, 5-20 g of glycerol, 2-20 g of dimethyl sulfoxide and the balance water. Hydrochloric acid doxepin serves as a main active ingredient, and glycerol and dimethyl sulfoxide serve as auxiliary materials. Hydrochloric acid doxepin has the effects of restraining nerve functional pain and mouth mucosa reactions, so that euphagiaof a patient is promoted, and normal treatment on the patient is guaranteed. The prepared gargle can effectively treat pain and abnormal food uptake symptoms shown due to mouth mucositis caused by chemoradiotherapy, and the gargle is different from medicine which is used for treating mouth mucositis caused by chemoradiotherapy and has definite clinical effects on the existing market. The gargle is simple in preparation process, controllable in quality and suitable for industrial production.

A compound medicament composition has doxepin and nicotinamide. 1g of medicament composition contains 5-100mg of doxepin and 1-100mg of nicotinamide. The inventive medicament composition is applied to the treatment of neurodermatitis or atopic dermatitis which has good effectiveness and uneasy recurrence.

The invention discloses a slow release preparation of Doxepin and its preparing process, wherein the raw materials of the preparation include Doxepin of a predetermined proportion, slow release matrix material and medicinal material, the preparation can be prepared into solid dispersing agent, wherein the medicament can be released slowly and continuously after being administrated, the effective concentration in blood can be maintained, and long action can be achieved. The advantages of the invention include decreased frequency of medicinal administration, improved patient's adaptability, lowered blood concentration peak-valley, increased medicinal effect and safety, and reduced total medicinal dose, thereby optimum curative effect can be achieved through minimum dose, thus the preparation is more suitable for patients.

Therapeutic compositions of doxepin and having a preponderance of the cis doxepin isomer over the trans doxepin isomer provide therapeutic effects for affective, painful, or allergic disorders without the sedative effects commonly experienced with compositions having a preponderance of the trans doxepin isomer.